IgA Nephropathy
118
18
25
50
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
15 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
7.6%
9 terminated out of 118 trials
84.7%
-1.8% vs benchmark
33%
39 trials in Phase 3/4
30%
15 of 50 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 50 completed trials
Clinical Trials (118)
Atacicept in Subjects With IgA Nephropathy
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
A Phase IIa Study in Primary IgA Nephropathy Patients
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States
Serum and Urinary sCD163 in IgA Nephropathy
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
TESTING -ON Post-Trial ObservatioNal Cohort Study
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Study of BHV-1400 in IgA Nephropathy
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy